RxDoctor Payments Data

Mark Segal, MD

Hematology & Oncology · Columbus, OHNPI 1093715385

Payments from drug & device makers

$14,886in general payments, 2019–2025

Across 613 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$3K
  • Eisai Inc.$863
  • Merck$732
  • AstraZeneca$629
  • Novartis$594
  • Daiichi Sankyo Inc.$448
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$14,66298%
  • Education$2242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exelixis Inc.8$2,813
Eisai Inc.44$863
Merck31$732
AstraZeneca(2 entities)35$629
Novartis33$594
Daiichi Sankyo Inc.19$448
Takeda Pharmaceuticals U.S.A., Inc.24$445
Pfizer20$437
Gilead(2 entities)21$369
Incyte Corporation17$368
Seagen Inc.13$350
Bristol Myers Squibb16$287
Astellas Pharma US Inc13$280
Beigene USA, Inc.12$259
Genentech USA, Inc.14$257
EMD Serono, Inc.15$248
Lilly USA, LLC11$238
Taiho Oncology, Inc.13$227
Johnson & Johnson12$225
GSK9$209
Karyopharm Therapeutics Inc.11$208
E.r. Squibb & Sons, L.L.C.12$198
Amgen12$197
Array Biopharma Inc10$196
Jazz Pharmaceuticals Inc.7$194
Sobi, Inc7$191
Tersera Therapeutics LLC8$190
Sanofi10$189
Regeneron Healthcare Solutions, Inc.8$180
AbbVie6$152
Stemline Therapeutics Inc.8$147
Pharmacyclics LLC, An Abbvie Company7$142
Ipsen Biopharmaceuticals, Inc7$134
Springworks Therapeutics, Inc.5$133
Geron Corporation4$116
Servier Pharmaceuticals LLC6$108
Amneal Pharmaceuticals LLC5$105
Pharmacosmos Therapeutics Inc.6$105
Blueprint Medicines Corporation5$95
AVEO Pharmaceuticals, Inc.5$88
Agios Pharmaceuticals, Inc.5$86
Adaptive Biotechnologies Corporation4$84
Coherus Oncology, Inc.5$83
Sun Pharmaceutical Industries Inc.3$66
Rigel Pharmaceuticals, Inc.4$65
Genmab U.S., Inc.4$63
Beone Medicines USA, Inc.2$61
G1 Therapeutics, Inc.3$59
CTI Biopharma Corp.3$57
ADC Therapeutics America, Inc.4$56
Mirati Therapeutics, Inc.2$51
Tempus AI, Inc2$48
Acceleron Pharma, Inc.3$47
Accord Healthcare, Inc.1$43
Pharmaessentia USA Corporation2$42
AMAG Pharmaceuticals, Inc.2$39
EUSA Pharma (US) LLC2$38
Recordati_rare_diseases_inc.2$38
Bayer2$35
Spectrum Pharmaceuticals Inc.2$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,886 in reported general payments places this provider in the 55th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$975,365
Medicare patients
264
Services billed
31,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide50$843,580
ImbruvicaIbrutinib48$631,802
PomalystPomalidomide20$461,839
JakafiRuxolitinib Phosphate25$409,236
BrukinsaZanubrutinib25$379,415
IbrancePalbociclib24$315,608
XtandiEnzalutamide16$226,611
Lenalidomide13$220,288
AlecensaAlectinib Hcl11$198,955
TagrissoOsimertinib Mesylate11$185,323
XareltoRivaroxaban15$18,175
Oxycodone Hcl68$2,789
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen60$2,335
Letrozole62$1,838
Exemestane16$1,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$287$843,58050 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$142$631,80248 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$198$461,83920 claims
Incyte CorporationJakafi$368$409,23625 claims
Beigene USA, Inc.Brukinsa$259$379,41525 claims
PfizerIbrance$437$315,60824 claims
Astellas Pharma US IncXtandi$280$226,61116 claims
Genentech USA, Inc.Alecensa$257$198,95511 claims
AstraZenecaTagrisso$629$185,32311 claims
Johnson & JohnsonXarelto$225$18,17515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →